{
    "clinical_study": {
        "@rank": "78749", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and\n      female subjects with hair loss."
        }, 
        "brief_title": "A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)", 
        "condition": [
            "Androgenetic Alopecia", 
            "Male Pattern Baldness", 
            "Female Pattern Baldness"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Alopecia", 
                "Alopecia Areata"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female volunteers 18-50 years old, inclusive.\n\n          -  Women of childbearing potential must use an adequate form of contraception during\n             study participation.\n\n          -  Hair loss consistent with Grade III-Vertex, IV, or V based on the based on the\n             Norwood-Hamilton Scale providing there is bridging of hair in the anterior edge of\n             the vertex circle, or class 1 or class 2 based on the Ludwig scale.\n\n          -  Able to provide informed consent after risks and benefits of the study have been\n             explained.\n\n          -  Be willing to undergo all study procedures.\n\n          -  Ability to communicate effectively with study personnel.\n\n          -  Have no clinically significant disease or abnormal laboratory evaluations taken at\n             the screening visit.\n\n          -  Agree to abstain from use of any hair growth affecting oral or topical medication\n             including over the counter and herbal medications, minoxidil, finasteride or\n             dutasteride during the course of this study; also agrees to abstain from shaving the\n             head during the course of the study.\n\n        Exclusion Criteria:\n\n          -  Women who are pregnant or lactating.\n\n          -  Known sensitivity to DMEM/F-12 or any component of the study material.\n\n          -  Known hypersensitivity to clindamycin hydrochloride, amphotericin B or streptomycin\n             sulfate.\n\n          -  Subjects who have used minoxidil or any oral or topical medication including over the\n             counter and herbal medications for the treatment of hair loss within 6 months of\n             study screening, or finasteride or dutasteride within 12 months of study screening.\n\n          -  A history of drug or alcohol abuse within 1 year of study enrollment.\n\n          -  Participation in any other investigational study within 30 days or six half lives of\n             its biologic activity, whichever is longer, before the scalp excision visit(s), and\n             during the time enrolled in this study.\n\n          -  Clinically significant medical or psychiatric illness currently or within 30 days of\n             study screening as determined by the investigator.\n\n          -  Clinically significant symptoms of any acute illness within 30 days prior to excision\n             day.\n\n          -  Any condition that compromises the ability to understand or comply with study\n             requirements.\n\n          -  Clinically significant abnormal laboratory parameters.\n\n          -  A positive result at screening for human immunodeficiency virus (HIV 1 or 2),\n             Hepatitis B or C, HTLV I/II.\n\n          -  Clinically significant dermatologic condition in donation or study zones.\n\n          -  Prior surgery in the donor or study zones.\n\n          -  Insufficient hair or scarring in the donor area that might impact cell growth.\n\n          -  Any disease or condition (medical or surgical) that, in the opinion of the\n             investigator, might compromise hematologic, cardiovascular, pulmonary, renal,\n             gastrointestinal, hepatic, or central nervous system function; or any condition that\n             would place the subject at increased risk."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "34", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01669746", 
            "org_study_id": "CA-0006931"
        }, 
        "intervention": {
            "arm_group_label": "Treatment", 
            "description": "A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.", 
            "intervention_name": "Autologous cultured mixed population of dermal cells", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Androgenetic Alopecia", 
            "Male Pattern Baldness", 
            "Female Pattern Baldness", 
            "Hair Loss", 
            "Baldness"
        ], 
        "lastchanged_date": "July 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Tucson", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85710"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Rosa", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95405"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80239"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Pinellas Park", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33781"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Akron", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44311"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29650"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "Radiant Research, Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multi-center, Phase 2 Study of Ji Gami(TM) CN That Evaluates the Efficacy and Safety of ex Vivo-cultured, Expanded, Occipital Autologous Dermal and Epidermal Cells, Injected Into the Hair Loss Area of the Scalp of Male and Female Subjects With Alopecia", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change from baseline in hair number", 
                "safety_issue": "No", 
                "time_frame": "24 weeks post-injection"
            }, 
            {
                "measure": "Change from baseline in hair width", 
                "safety_issue": "No", 
                "time_frame": "24 weeks post-injection"
            }, 
            {
                "measure": "Time course of any treatment benefit", 
                "safety_issue": "No", 
                "time_frame": "24 week post-injection"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01669746"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Aderans Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Aderans Research Institute", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}